Velmanase alfa-tycv: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 May 2024

  • curprev 23:0723:07, 20 May 2024‎ Rithish Nimmagadda talk contribs‎ 7,709 bytes +7,709‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac..."
Retrieved from "https://www.wikidoc.org/index.php/Velmanase_alfa-tycv"